Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Inventiva S.A. (NASDAQ: IVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
Inventiva reports its 2024 full year results and provides a business update
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment